[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:diffuse-midline-glioma:relaxin-3":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Diffuse Midline Glioma","RELAXIN 3",4,[8,16,22,28],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06894979","Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma",[12],"Phase 1","RECRUITING","2026-08-03T00:59:21.983893Z","2026-07-05T05:32:16.705849Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07223034","A Study of 177Lu-PSMA-617 in People With Gliomas",[12],"2026-08-26T02:16:23.080181Z","2026-07-05T05:32:16.669055Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06860594","Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma",[12],"2026-08-26T02:18:58.141497Z","2026-06-14T18:39:22.242053Z",{"nct_id":29,"title":30,"phases":31,"status":32,"updated_at":33,"content_modified":34},"NCT06896110","Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:15:00.557154Z","2026-06-16T05:54:07.840721Z"]